Epirubicin plus SHR1210

Phase 2UNKNOWN
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Small Cell Lung Cancer Extensive Stage

Conditions

Small Cell Lung Cancer Extensive Stage

Trial Timeline

Feb 1, 2019 → May 31, 2020

About Epirubicin plus SHR1210

Epirubicin plus SHR1210 is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Small Cell Lung Cancer Extensive Stage. The current trial status is unknown. This product is registered under clinical trial identifier NCT03755115. Target conditions include Small Cell Lung Cancer Extensive Stage.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03755115Phase 2UNKNOWN

Competing Products

20 competing products in Small Cell Lung Cancer Extensive Stage

See all competitors
ProductCompanyStageHype Score
BBP-398 with nivolumabBridgeBio PharmaPhase 1
30
Pemetrexed + CarboplatinEli LillyPhase 3
77
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
SelpercatinibEli LillyPre-clinical
23
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
77
NBTXR3NanobiotixPhase 1/2
36
PemetrexedEli LillyPre-clinical
23
pemetrexed + erlotinibEli LillyPhase 2
52
LY3295668 ErbumineEli LillyPhase 1
33
FYB206 + FYB206 + KeytrudaFormycon AGPhase 3
69
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
44
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
69
pemetrexed + cisplatinEli LillyPhase 2
52
gemcitabine + carboplatin + cisplatinEli LillyPhase 2
52
CetuximabEli LillyPhase 1
33
pemetrexed + docetaxelEli LillyPhase 3
77
enzastaurin + pemetrexed + docetaxel + carboplatinEli LillyPhase 2
52
PemCarbo + Pem onlyEli LillyPhase 3
77
TNG456 + abemaciclibEli LillyPhase 1/2
41
pemetrexed + cisplatinEli LillyPhase 1/2
41